StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics cash

Cash and short-term investments held at the end of each period.

Kyverna Therapeutics's cash was $170.60M at Sep 30, 2026. For fiscal 2025 it was $279.30M, down 2.3% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$279.30M-2.3%
FY2024Dec 31, 2024$286.00M+397.0%
FY2023Dec 31, 2023$57.54M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$170.60M-0.3%
Q2 FY2026Jun 30, 2026$199.40M-5.8%
Q1 FY2026Mar 31, 2026$236.40M-2.6%
Q4 FY2025Dec 31, 2025$279.30M-2.3%
Q3 FY2025Sep 30, 2025$171.10M-46.8%
Q2 FY2025Jun 30, 2025$211.70M-38.9%
Q1 FY2025Mar 31, 2025$242.60M-34.4%
Q4 FY2024Dec 31, 2024$286.00M+397.0%
Q3 FY2024Sep 30, 2024$321.60M+1300.3%
Q2 FY2024Jun 30, 2024$346.20M+548.0%
Q1 FY2024Mar 31, 2024$369.80M+829.5%
Q4 FY2023Dec 31, 2023$57.54M–
Q3 FY2023Sep 30, 2023$22.97M–
Q2 FY2023Jun 30, 2023$53.43M–
Q1 FY2023Mar 31, 2023$39.79M–

More Kyverna Therapeutics figures

See a number that looks wrong?